PMID- 24489972
OWN - NLM
STAT- MEDLINE
DCOM- 20141006
LR  - 20220316
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 1
DP  - 2014
TI  - Urinary concentration of monocyte chemoattractant protein-1 in idiopathic 
      glomerulonephritis: a long-term follow-up study.
PG  - e87857
LID - 10.1371/journal.pone.0087857 [doi]
LID - e87857
AB  - BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1), which is up regulated in 
      kidney diseases, is considered a marker of kidney inflammation. We examined the 
      value of urine MCP-1 in predicting the outcome in idiopathic glomerulonephritis. 
      METHODS: Between 1993 and 2004, 165 patients (68 females) diagnosed with 
      idiopathic proteinuric glomerulopathy and with serum creatinine <150 micromol/L at 
      diagnosis were selected for the study. Urine concentrations of MCP-1 were 
      analyzed by ELISA in early morning spot urine samples collected on the day of the 
      diagnostic kidney biopsy. The patients were followed until 2009. The progression 
      rate to end-stage kidney disease was calculated using Kaplan-Meier survival 
      analysis. End-stage kidney disease (ESKD) was defined as the start of kidney 
      replacement therapy during the study follow-up time. RESULTS: Patients with 
      proliferative glomerulonephritis had significantly higher urinary MCP-1 excretion 
      levels than those with non-proliferative glomerulonephritis (p<0.001). The 
      percentage of patients whose kidney function deteriorated significantly was 39.0% 
      in the high MCP-1 excretion group and 29.9% in the low MCP-1 excretion group. 
      However, after adjustment for confounding variables such as glomerular filtration 
      rate (GFR) and proteinuria, there was no significant association between urine 
      MCP-1 concentration and progression to ESKD, (HR=1.75, 95% CI=0.64-4.75, p=0.27). 
      CONCLUSION: Our findings indicate that progression to end-stage kidney disease in 
      patients with idiopathic glomerulopathies is not associated with urine MCP-1 
      concentrations at the time of diagnosis.
FAU - Tofik, Rafid
AU  - Tofik R
AD  - Department of Nephrology, Lund University, Lund, Sweden.
FAU - Ohlsson, Sophie
AU  - Ohlsson S
AD  - Department of Nephrology, Lund University, Lund, Sweden.
FAU - Bakoush, Omran
AU  - Bakoush O
AD  - Department of Nephrology, Lund University, Lund, Sweden ; Department of Internal 
      Medicine, UAE University, Al-Ain, United Arab Emirates.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140129
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Biomarkers/urine
MH  - Chemokine CCL2/*urine
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Glomerulonephritis/drug therapy/mortality/*urine
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Kaplan-Meier Estimate
MH  - Kidney/physiopathology
MH  - Kidney Failure, Chronic/mortality/*urine
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Risk
MH  - Treatment Outcome
PMC - PMC3906252
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/02/04 06:00
MHDA- 2014/10/07 06:00
PMCR- 2014/01/29
CRDT- 2014/02/04 06:00
PHST- 2013/10/08 00:00 [received]
PHST- 2013/12/30 00:00 [accepted]
PHST- 2014/02/04 06:00 [entrez]
PHST- 2014/02/04 06:00 [pubmed]
PHST- 2014/10/07 06:00 [medline]
PHST- 2014/01/29 00:00 [pmc-release]
AID - PONE-D-13-40979 [pii]
AID - 10.1371/journal.pone.0087857 [doi]
PST - epublish
SO  - PLoS One. 2014 Jan 29;9(1):e87857. doi: 10.1371/journal.pone.0087857. eCollection 
      2014.